Cargando…

The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries

Demonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, N., Mounier-Jack, S., Gallagher, K. E., Kabakama, S., Griffiths, U. K., Feletto, M., LaMontagne, D. S., Burchett, H. E. D., Watson-Jones, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027708/
https://www.ncbi.nlm.nih.gov/pubmed/27159786
http://dx.doi.org/10.1080/21645515.2016.1178433
_version_ 1782454283718885376
author Howard, N.
Mounier-Jack, S.
Gallagher, K. E.
Kabakama, S.
Griffiths, U. K.
Feletto, M.
LaMontagne, D. S.
Burchett, H. E. D.
Watson-Jones, D.
author_facet Howard, N.
Mounier-Jack, S.
Gallagher, K. E.
Kabakama, S.
Griffiths, U. K.
Feletto, M.
LaMontagne, D. S.
Burchett, H. E. D.
Watson-Jones, D.
author_sort Howard, N.
collection PubMed
description Demonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, including potential drawbacks and how value for national scale-up might be increased. Data from a systematic review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8 national programmes implemented between 2007-2015 (89 years' experience). Initial demonstration projects quickly provided consistent lessons. Value would increase if projects were designed to inform sustainable national scale-up. Well-designed projects can test multiple delivery strategies, implementation for challenging areas and populations, and integration with national systems. Introduction of vaccines or other health interventions, particularly those involving new target groups or delivery strategies, needs flexible funding approaches to address specific questions of scalability and sustainability, including learning lessons through phased national expansion.
format Online
Article
Text
id pubmed-5027708
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-50277082016-11-01 The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries Howard, N. Mounier-Jack, S. Gallagher, K. E. Kabakama, S. Griffiths, U. K. Feletto, M. LaMontagne, D. S. Burchett, H. E. D. Watson-Jones, D. Hum Vaccin Immunother Commentaries Demonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, including potential drawbacks and how value for national scale-up might be increased. Data from a systematic review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8 national programmes implemented between 2007-2015 (89 years' experience). Initial demonstration projects quickly provided consistent lessons. Value would increase if projects were designed to inform sustainable national scale-up. Well-designed projects can test multiple delivery strategies, implementation for challenging areas and populations, and integration with national systems. Introduction of vaccines or other health interventions, particularly those involving new target groups or delivery strategies, needs flexible funding approaches to address specific questions of scalability and sustainability, including learning lessons through phased national expansion. Taylor & Francis 2016-05-09 /pmc/articles/PMC5027708/ /pubmed/27159786 http://dx.doi.org/10.1080/21645515.2016.1178433 Text en © 2016 The Author(s). Published with license by Taylor & Francis. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentaries
Howard, N.
Mounier-Jack, S.
Gallagher, K. E.
Kabakama, S.
Griffiths, U. K.
Feletto, M.
LaMontagne, D. S.
Burchett, H. E. D.
Watson-Jones, D.
The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title_full The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title_fullStr The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title_full_unstemmed The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title_short The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
title_sort value of demonstration projects for new interventions: the case of human papillomavirus vaccine introduction in low- and middle-income countries
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027708/
https://www.ncbi.nlm.nih.gov/pubmed/27159786
http://dx.doi.org/10.1080/21645515.2016.1178433
work_keys_str_mv AT howardn thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT mounierjacks thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT gallagherke thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT kabakamas thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT griffithsuk thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT felettom thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT lamontagneds thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT burchetthed thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT watsonjonesd thevalueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT howardn valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT mounierjacks valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT gallagherke valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT kabakamas valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT griffithsuk valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT felettom valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT lamontagneds valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT burchetthed valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries
AT watsonjonesd valueofdemonstrationprojectsfornewinterventionsthecaseofhumanpapillomavirusvaccineintroductioninlowandmiddleincomecountries